# GenAns Biotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genans-biotech

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.genansco.com/
- Latest round: Series A (Jul 30, 2026)
- Investors on record: 10

## About

Based in Beijing, China and founded in 2022, GenAns Biotechnology Co., Ltd., trading as GenAns Biotech, focusing on developing advanced gene delivery systems for therapeutic applications. In July 2026, GenAns Biotech raised a series A funding led by Tppoly Capital, with participation from Huatai Zijin Investment, Gaorong Ventures, and other investors.

GenAns Biotech specializes in innovative gene therapies focused on central nervous system (CNS) disorders and ophthalmic diseases. The company implements advanced neurobiological knowledge and high-throughput screening technologies to develop gene delivery systems targeting specific cells and tissues for therapeutic applications. Their primary offerings include an AAV high-throughput directional evolution screening platform, a functional protein screening platform, and a drug development platform, all aimed at addressing the unmet clinical needs associated with hereditary and neurological diseases.

GenAns Biotech's revenue generation model is primarily based on partnerships and collaborations with healthcare institutions and research organizations. 

The company will use the latest funding to advance the clinical validation of the company's multiple core pipelines, accelerate the development of backup pipelines and the process of dual registration in China and the United States, and further strengthen the company's platform capabilities in cutting-edge brain science technologies such as chemical genetics and optogenetics, so as to continuously produce globally innovative drugs that utilize precise neuromodulation to treat refractory brain diseases.

## Funding rounds

- Series A, Jul 30, 2026 — Gaorong Ventures, Huatai Zijin Investment, Tppoly Capital
- Series C, Jan 14, 2026 — Huatai Zijin Investment, Biossom Investment Management, Beijing Capital Science and Technology Development Group Investment Management, Tao Capital
- Series B, Jan 8, 2025 — Shunxi Fund
- Angel, Dec 27, 2022 — Tao Capital, Changkejin  Investment, Zhongguancun Development Venture, Yishang Huicheng Investment

## Investors

- Tao Capital (https://capitalatlas.ai/funds/tao-capital) — Angel, Series C
- Changkejin  Investment — Angel
- Zhongguancun Development Venture (https://capitalatlas.ai/funds/zhongguancun-development-venture) — Angel
- Yishang Huicheng Investment (https://capitalatlas.ai/funds/yishang-huicheng-investment) — Angel
- Shunxi Fund (https://capitalatlas.ai/funds/shunxi-fund) — Series B
- Huatai Zijin Investment (https://capitalatlas.ai/funds/huatai-zijin-investment) — Series C, Series A
- Biossom Investment Management (https://capitalatlas.ai/funds/biossom-investment-management) — Series C
- Beijing Capital Science and Technology Development Group Investment Management (https://capitalatlas.ai/funds/beijing-capital-science-and-technology-development-group-inv) — Series C
- Gaorong Ventures (https://capitalatlas.ai/funds/gaorong-ventures) — Series A
- Tppoly Capital (https://capitalatlas.ai/funds/tppoly-capital) — Series A